Author:
Bano Shazia,Alburquerque Jose Quilez,Roberts Harrison James,Pang Sumiao,Huang Huang-Chiao,Hasan Tayyaba
Funder
NCI
National Institutes of Health
Reference53 articles.
1. Differentiation of liposomal irinotecan from dose-dense non-liposomal irinotecan in patient-derived pancreatic cancer xenograft tumor models;Barbier;Proc. Am. Soc. Clin. Oncol.,2020
2. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Sung;CA Cancer J. Clin.,2021
3. Pancreatic ductal adenocarcinoma: characteristics of tumor microenvironment and barriers to treatment;Kane;J. Adv. Pract. Oncol.,2020
4. Locally advanced pancreatic ductal adenocarcinoma: challenges and progress;Barcellini;Onco. Targets. Ther.,2020
5. Pancreatic cancer: advances and challenges;Halbrook;Cell,2023